Ipamorelin Mechanism of Action: The Most Selective GHRP — Research Guide | Biohackslabs
Ipamorelin is a pentapeptide GHRP that selectively activates the ghrelin receptor (GHS-R1a) on pituitary somatotrophs to stimulate growth hormone release without meaningfully elevating cortisol, prolactin, or ACTH — a selectivity profile preclinical studies show is uniquely clean among growth hormone secretagogues.
Ipamorelin vs Other GHRPs: Selectivity Comparison
| Parameter | Ipamorelin | GHRP-2 | GHRP-6 |
|---|---|---|---|
| Receptor target | GHS-R1a (selective) | GHS-R1a + additional subtypes | GHS-R1a + additional subtypes |
| GH release | Strong, pulsatile | Strong, pulsatile | Strong, pulsatile |
| Cortisol elevation | None at research doses | Significant | Moderate |
| ACTH elevation | None at research doses | Significant | Moderate |
| Prolactin elevation | None at research doses | Moderate | Moderate |
| Appetite stimulation | Minimal | Moderate | Strong (ghrelin-like) |
| Primary research use | Clean GH pulse studies | GH axis stimulation | GH axis stimulation |
Mechanism of Action
Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a synthetic pentapeptide that functions as a selective agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a), located on anterior pituitary somatotrophs and hypothalamic neurons. Upon receptor binding, downstream signaling through the Gq/11 — phospholipase C — IP3 — intracellular calcium release cascade triggers pulsatile GH vesicle exocytosis. Hypothalamic GHS-R1a activation is thought to attenuate somatostatin tone, disinhibiting GH release at the pituitary level.
Selectivity Research
Preclinical studies by Raun et al. (1998) and subsequent comparative work demonstrate that ipamorelin does not produce statistically significant elevations in ACTH, cortisol, or prolactin even at doses exceeding 200-fold the GH-releasing ED50. This selectivity makes ipamorelin the reference compound in preclinical research designs requiring isolated GH axis stimulation without confounding HPA axis activation. In rodent models, GH pulses following ipamorelin administration show peak amplitude of 50-100 ng/mL at 15-30 minutes post-administration, with complete resolution within 3 hours, matching physiological pulse kinetics.
Stack Compatibility
Ipamorelin is the most common GHRP component of the CJC-1295 + Ipamorelin stack. CJC-1295 activates the GHRH receptor (Gs/cAMP pathway) while Ipamorelin activates GHS-R1a (Gq/IP3/Ca2+ pathway). Dual receptor activation through independent second messenger systems produces synergistic GH pulse amplification. Available as the GH Recovery Stack at biohackslabs.com for research purposes only.
FAQ
Why is ipamorelin called the most selective GHRP?
Ipamorelin is termed the most selective GHRP because it activates only GHS-R1a without meaningfully engaging receptors responsible for cortisol, ACTH, or prolactin release. Studies show this selectivity holds at doses 200x the GH-releasing ED50. Competing GHRPs like GHRP-2 and GHRP-6 produce measurable cortisol and ACTH elevations at similar GH-stimulating doses, making them less suitable for research designs requiring isolated GH axis modulation.
How does ipamorelin stimulate GH release?
Ipamorelin binds GHS-R1a on anterior pituitary somatotrophs, activating Gq/11 protein which activates phospholipase C, increasing IP3 and releasing intracellular calcium stores. This calcium surge triggers GH vesicle exocytosis, producing a discrete, pulsatile GH release event. Simultaneously, hypothalamic GHS-R1a activation reduces somatostatin inhibitory tone, potentiating the pituitary response.